...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: To paraphrase…

,,, I doubt this present team is capable of much more than what we have witnessed to date...if either of these companies do make the big times it will most likely be under a new management team put in by the major insiders and the previous team handsomely rewarded for passing over the reigns,,,...the question is,,,will we take part in any winnings??....looks more like we would get taken out for less than the individual components could be worth,,,but I dont have next weeks news paper today,,,,jmo

Share
New Message
Please login to post a reply